Catherine M. Kelly

7.9k citations

149 papers · 3.6k indexed · 2 hit papers · h-index 32

Cancer Research top 1%
- Breast Cancer Treatment Studies 33
- Cancer Genomics and Diagnostics 13
Oncology top 1%
- HER2/EGFR in Cancer Research 28
- Cancer Treatment and Pharmacology 22
- Cancer Immunotherapy and Biomarkers 12
Pulmonary and Respiratory Medicine top 2%
- Advanced Breast Cancer Therapies 28
Family Practice top 5%
Genetics top 5%
- BRCA gene mutations in cancer 11
- Estrogen and related hormone effects 9

Co-authors: Lajos Pusztai Melanie Smith Giuseppe Viale Minh Duong-Hua David N. Juurlink Tara Gomes Lawrence Paszat K. I. Pritchard
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology (29 papers)Diabetes Care (1 paper)JNCI Journal of the National Cancer Institute (1 paper)
Partner nations: Ireland United States United Kingdom

In The Last Decade

Catherine M. Kelly

144 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Catherine M. Kelly

Since Specialization

Citations

This map shows the geographic impact of Catherine M. Kelly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine M. Kelly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine M. Kelly more than expected).

Fields of papers citing papers by Catherine M. Kelly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine M. Kelly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine M. Kelly. The network helps show where Catherine M. Kelly may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Catherine M. Kelly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Catherine M. Kelly Line = papers co-authored together Catherine M. Kelly links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Refining source-specific lung cancer risk assessment from PM2.5-bound PAHs: Integrating component-based potency factors and machine learning in Ningbo, China Ecotoxicology and Environmental Safety ·Lord Famiyeh,Ke Chen,Fiseha B. Tesema,Catherine M. Kelly,Dongsheng Ji,Hang Xiao,Lei Tong,Zongshuang Wang,Jun He	2025	2
2	Multimodal, Technology-Assisted Intervention for the Management of Menopause after Cancer Improves Cancer-Related Quality of Life—Results from the Menopause after Cancer (Mac) Study Cancers ·Fionán Donohoe,Yvonne O’Meara,Aidín Roberts,Louise Comerford,Ivaila Valcheva,Una Kearns,Marie Galligan,Michaela J. Higgins,Alasdair L. Henry,Catherine M. Kelly,Janice M. Walshe,Martha Hickey,Donal J. Brennan	2024	0
3	LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study Annals of Oncology ·Luca Gianni,Chiun‐Sheng Huang,Daniel Egle,Begoña Bermejo,Claudio Zamagni,Marc Thill,A. Antón Torres,Giampaolo Bianchini,E. Sevillano Fernandez,Stefania Russo,Eva Ciruelos,Richard Greil,Semiglazov Vf,Marco Colleoni,Catherine M. Kelly,Gabriella Mariani,Lucia Del Mastro,Riccardo Spezia,Hoda Ali,Giuseppe Viale	2023	10
4	Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studybreakdown → Annals of Oncology ·Luca Gianni,Chiun‐Sheng Huang,Daniel Egle,Begoña Bermejo,C. Zamagni,Marc Thill,A. Antón,Stefania Zambelli,Giampaolo Bianchini,Salvatore Russo,Eva Ciruelos,Richard Greil,Semiglazov Vf,Marco Colleoni,Catherine M. Kelly,Gabriella Mariani,Lucia Del Mastro,I. Maffeis,Pinuccia Valagussa,Giuseppe Viale	2022	204
5	Using menopausal hormone therapy after a cancer diagnosis in Ireland Irish Journal of Medical Science (1971 -) ·Fionán Donohoe,Yvonne O’Meara,Aidín Roberts,Louise Comerford,Catherine M. Kelly,Janice M. Walshe,Deirdre Lundy,Martha Hickey,Donal J. Brennan	2022	7
6	The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study Contemporary Clinical Trials Communications ·Fionán Donohoe,Yvonne O’Meara,Aidín Roberts,Louise Comerford,Catherine M. Kelly,Janice M. Walshe,Michelle Peate,Martha Hickey,Donal J. Brennan	2021	2
7	Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland Breast Cancer Research and Treatment ·Lynda McSorley,Mehala Tharmabala,Fathiya Al Rahbi,K. McSorley,Sonya Chew,Denis Evoy,James Geraghty,R S Prichard,Jane Rothwell,Damian McCartan,E. McDermott,Maccon Keane,Michael J. Kennedy,Séamus O’Reilly,Steve Millen,John Crown,Lillian M. Smyth,Catherine M. Kelly,Cecily Quinn,Janice M. Walshe	2021	6
8	Where youth matters—clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancer Irish Journal of Medical Science (1971 -) ·Megan Greally,Jennifer Kielty,Geoffrey Alan Watson,Geoffrey Das,Christina W Malouf,Lynda McSorley,Niamh Coleman,Cecily Quinn,Enda McDermott,Giuseppe Gullo,John Crown,Ruth Prichard,Catherine M. Kelly,Janice M. Walshe	2018	4
9	FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer Annals of Oncology ·Kathleen N. Moore,Ignace Vergote,Ana Oaknin,Nicoletta Colombo,Susana Banerjee,Amit M. Oza,Patricia Pautier,Catherine M. Kelly,Karim Malek,Michael J. Birrer	2017	1
10	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer The Oncologist ·Libero Santarpia,Giulia Bottai,Catherine M. Kelly,Balázs Győrffy,Borbála Székely,Lajos Pusztai	2016	38
11	Vismodegib in the treatment of advanced BCC. PubMed ·G. J. O'KANE,Tomás G. Lyons,Ian A. McDonald,Nikki Mulligan,F. J. Moloney,D. Stark Murray,Catherine M. Kelly	2014	4
12	Benefit risk assessment and update on the use of docetaxel in the management of breast cancer Cancer Management and Research ·Catherine M. Kelly,Scheryll Alken	2013	34
13	Using Multiple Targeted Therapies in Oncology: Considerations for Use, and Progress to Date in Breast Cancer Drugs ·Catherine M. Kelly,Aman U. Buzdar	2013	12
14	Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer Journal of Clinical Oncology ·Anna M. Sawka,Sharon E. Straus,Lorne Rotstein,James D. Brierley,Richard Tsang,L. Sylvia,Phillip Segal,Catherine M. Kelly,Afshan Zahedi,Jeremy L. Freeman,Philip Solomon,Jennifer Anderson,Kevin E. Thorpe,Amiram Gafni,Gary Rodin,David P. Goldstein	2012	37
15	Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Annals of Oncology ·Catherine M. Kelly,Kathleen I. Pritchard,Maureen Trudeau,Eleni Andreopoulou,Kenneth R. Hess,Lajos Pusztai	2011	20
16	Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ ·Catherine M. Kelly,David N. Juurlink,Tara Gomes,Minh Duong-Hua,K. I. Pritchard,Peter C. Austin,Lawrence Paszat	2010	311
17	Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers Cancer ·Catherine M. Kelly,Savitri Krishnamurthy,Giampaolo Bianchini,Jennifer K. Litton,Ana M. Gonzalez‐Angulo,Gabriel N. Hortobágyi,Lajos Pusztai	2010	80
18	A randomized controlled trial to measure the effectiveness of a sacral wedge in preventing postoperative back pain following trans‐urethral resection of the prostate (TURP) in lithotomy position Journal of Clinical Nursing ·Peter Pietrocola,Robin Riley,Christine Beanland,Catherine M. Kelly,Jenny Radnell	2004	2
19	A novel amino-terminally glycated analogue of glucose-dependent insulinotropic polypeptide (GIP), with prolonged insulinotropic activity in type 2 diabetes mellitus Diabetes ·Lindsay,Stb Au,Catherine M. Kelly,Finbarr O’Harte,Peter R. Flatt,PM Bell	2002	9
20	Colitis X in the horse New Zealand Veterinary Journal ·Catherine M. Kelly	1972	2

About Catherine M. Kelly

Catherine M. Kelly is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 149 papers that have together received 3.6k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (33 papers), Advanced Breast Cancer Therapies (28 papers), HER2/EGFR in Cancer Research (28 papers), Cancer Treatment and Pharmacology (22 papers), Cancer Genomics and Diagnostics (13 papers), Cancer Immunotherapy and Biomarkers (12 papers), BRCA gene mutations in cancer (11 papers) and Estrogen and related hormone effects (9 papers). The work is most often cited by research in Cancer Research (1.1k citations), Oncology (1.8k citations) and Pulmonary and Respiratory Medicine (842 citations). Catherine M. Kelly has collaborated with scholars based in Ireland, United States and United Kingdom. Frequent co-authors include Lajos Pusztai, Melanie Smith, Giuseppe Viale, Minh Duong-Hua, David N. Juurlink, Tara Gomes, Lawrence Paszat, K. I. Pritchard, Peter C. Austin and Clifford A. Hudis. Their work appears in journals such as Journal of Clinical Oncology, Diabetes Care and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact